Skip to main content
. 2024 Jan 18;30(7):1240–1247. doi: 10.1158/1078-0432.CCR-23-2513

Figure 2.

Figure 2. Case study: maintenance olaparib in wild-type germline BRCA metastatic triple-negative breast cancer. PR, partial response.

Case study: maintenance olaparib in wild-type germline BRCA metastatic triple-negative breast cancer. PR, partial response.